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A B S T R A C T
Purpose
We previously validated disease-free survival (DFS) as a surrogate for overall survival (OS) in
fluorouracil-based adjuvant colon cancer clinical trials. New therapies have extended survival after
recurrence from 1 to approximately 2 years. We examined the possible impact of this improve-
ment on the DFS/OS association.
Methods
The Adjuvant Colon Cancer Endpoints (ACCENT) data set of 20,898 patients was analyzed. In an
exploratory fashion, time from recurrence to death in patients experiencing recurrence was
extended using several algorithms, and the association of DFS after 3 years of median follow-up
and OS after varying lengths of follow-up (median of 5, 6, and 7 years) was assessed.
Results
Seven thousand four hundred two patients (35%) experienced recurrence. Median time from
recurrence to death was 24 months in the hypothetical data sets. When times from recurrence to
death were doubled, the association between treatment effects on DFS and 5-year OS was
modest (R2  0.51 for both 2- and 3-year DFS) but remained strong for DFS and 6-year OS (R2 
0.67 for both 2- and 3-year DFS) and 7-year OS (R2  0.70 for both 2- and 3-year DFS). The reduced
DFS/OS association with extended survival after recurrence was greater in stage II than stage III
patients. Multiple simulations provided consistent findings.
Conclusion
Extended survival after recurrence reduces the association between treatment effects on 3-year
DFS and 5-year OS, particularly in stage II patients; longer follow-up strengthens the association.
In modern adjuvant trials, 6 or 7 years may be required to demonstrate OS improvements, further
supporting DFS as the preferred primary end point for future adjuvant colon cancer clinical trials.
J Clin Oncol 28:460-465. © 2009 by American Society of Clinical Oncology
INTRODUCTION
In the past decade, multiple, incremental ad-
vances in the treatment of colon cancer have im-
proved patient outcomes in the advanced-disease
setting. Combination chemotherapy with fluorou-
racil (FU)/leucovorin (LV) plus oxaliplatin,1,2 as
well as FU/LV plus irinotecan,3 results in improved
progression-free survival and overall survival (OS)
when compared with FU/LV alone. At the trial
level, exposure to all three cytotoxic agents (FU/
LV, oxaliplatin, and irinotecan) at some point in
the treatment of advanced disease is associated
with prolonged median OS.4,5 Targeted therapies
such as bevacizumab, cetuximab, and panitu-
mumab have also extended progression-free sur-
vival or OS in the advanced-disease setting.6-10 In
addition, the use of postrecurrence metastasec-
tomy has been shown to result in long-term sur-
vival in selected patients.11
In the adjuvant setting, the Multicenter Inter-
national Study of Oxaliplatin/5FU-LV in the Adju-
vant Treatment of Colon Cancer (MOSAIC) trial
randomly assigned patients to oxaliplatin or not in
combination with FU/LV as postoperative therapy
for stage II and III colon cancer.12 In this trial, there
JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T
VOLUME 28  NUMBER 3  JANUARY 20 2010
460 © 2009 by American Society of Clinical Oncology
was a significant increase in disease-free survival (DFS) favoring the
oxaliplatin group, which led to the approval of oxaliplatin for adjuvant
therapy in stage III colon cancer. Among patients with stage III disease,
the beneficial effects observed for DFS at the 3-year time point were
maintained at 5 years, but oxaliplatin did not result in a significant
benefit in OS until 6 years of follow-up.13 These findings are supported
by the results of the National Surgical Adjuvant Breast and Bowel
Project (NSABP) C-07 trial, where oxaliplatin again provided a highly
significant improvement in 3-year DFS but a borderline improvement
in 5-year OS.14,15
The use of DFS with 3 years of median follow-up as a primary end
point in MOSAIC and NSABP C-07 was supported by analyses from
the Adjuvant Colon Cancer Endpoints (ACCENT) database, a pooled
database of data on individual patients with colon cancer from multi-
ple phase III clinical trials involving FU-based adjuvant therapy. The
initial ACCENT analysis showed a strong correlation between treat-
ment effects on DFS assessed after 3 years of median follow-up and
5-year OS.16 Subsequent analyses also demonstrated that the treat-
ment effect on DFS after 2 years of median follow-up was highly
associated with the effect on OS after 5 years of follow-up.17
Improvements in the detection and treatment of recurrent colon
cancer, including secondary resections, have translated into a median
OS from recurrence to death of approximately 2 years in recent
trials.13,15,18-20 In the initial ACCENT report, the median time from
recurrence to death was 12 months.16 This observation motivated the
current study to determine the impact of longer survival after recur-
rence on the association between DFS and OS in adjuvant colon
cancer therapy trials.
METHODS
The ACCENT data set consists of individual patient data from 18 trials that
investigated FU-based adjuvant therapy in colon cancer. These trials, con-
ducted from 1978 to 1999, involved 20,898 patients and 43 treatment arms (34
active treatment arms and nine surgery-only arms). Details regarding the
individual clinical trials and patient characteristics are listed in Appendix
Tables A1 and A2 (online only). Approval for this analysis was granted by the
Mayo Clinic Investigational Review Board; individual trials were approved
through local mechanisms at the time the trials were conducted.
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Fig 1. Scatter plots of hazard ratios by trial (disease-free survival [DFS] v overall survival [OS]). (A) Three-year DFS versus 5-year OS (actual data). (B) Three-year DFS
versus 5-year OS (hypothetical data, doubled time from recurrence to death). (C) Three-year DFS versus 6-year OS (hypothetical data, doubled time from recurrence
to death). (D) Three-year DFS versus 7-year OS (hypothetical data, doubled time from recurrence to death).
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We created multiple hypothetical data sets based on all patients in
ACCENT. In the primary hypothetical data set, for all patients who experi-
enced a recurrence, keeping all other factors identical, each patient’s time from
recurrence to death was doubled. In patients who experienced recurrence but
did not die in the follow-up period, the patient’s time from recurrence to
censoring was similarly doubled. The survival time remained unchanged for
patients without recurrence events. The association between treatment effects
on DFS assessed after 2 and 3 years of median follow-up (DFS-2 and DFS-3,
respectively) and the hypothetical OS after 5, 6, and 7 years of median
follow-up (OS-5, OS-6, and OS-7 respectively) was examined in the simulated
data set. Trial-level association (R2) between the two end points was estimated
by using a two-stage bivariate copula survival model.21 Briefly, the copula
model considers the association between the hazard ratios comparing treat-
ment with control within each trial, based on the complete data available for
each patient in each analysis after censoring. The trial-level R2 is based on a 0 to
1 scale; levels closer to 1 indicate a stronger association, thereby indicating a
better candidate for a surrogate end point.
The median follow-up time across all trials was greater than 8 years. For
all analyses, efforts were made to replicate the actual conduct of a clinical trial,
where patients enter over a period of several years and thus at any given
calendar date have differing durations of follow-up. For each analysis con-
ducted at a specific time point (eg, 3 years), the outcome data for each patient
were censored at the point in time at which the median follow-up in the trial
was 3 years. Thus, as the time for the OS analysis changed from 5 to 6 to 7 years,
the number of events available for analysis increased. In all calculations of
median follow-up, only patients without an event were considered in the
median calculation.
Analyses were performed for all patients and also separately for patients
with initial stage II and III disease. Additional simulations were performed by
extending survival after recurrence differentially for individual patients based
on patient-specific characteristics. Survival extensions were modified for the
use of adjuvant therapy, time from random assignment to recurrence, and
initial stage of colon cancer (I or II v III), factors previously shown to signifi-
cantly impact the time from recurrence to death.22 For each setting, time from
recurrence to death of individual patients was extended by a factor that de-
pended on that patient’s individual characteristics. On the basis of previously
reported hazard ratios for time from recurrence to death for each characteris-
tic,22 the multiplication factors were normalized such that the weighted aver-
age extension in the overall population equaled 2 (ie, a doubling of survival
after recurrence).
RESULTS
Among patients in the original ACCENT database, 7,402 (35%) of
20,898 patients experienced recurrence. Eleven percent of patients
died without recurrence, and 90% of patients who experienced recur-
rence subsequently died within the initial trial’s follow-up period. The
median time from recurrence to death was 12 months in the original
data set and 24 months in the hypothetical data sets.
In the original data set, the treatment effect on DFS-3 was highly
predictive of the effect on OS-5, with an R2 value of 0.75 (95% CI, 0.55
to 0.95; Fig 1A), as well as for OS-6 and OS-7, with R2 values of 0.78
(95% CI, 0.60 to 0.96) and 0.82 (95% CI, 0.67 to 0.97), respectively
(Table 1). The association between treatment effects on DFS-3 and
OS-5 deteriorated substantially in the hypothetical data set, with an R2
value of 0.51 (95% CI, 0.18 to 0.83; Fig 1B), but remained strong
between DFS-3 and OS-6, although not as strong as in the original data
set, with an R2 value of 0.67 (95% CI, 0.42 to 0.92; Fig 1C). When the
hypothetical data set follow-up for OS was extended to 7 years, the
correlation showed modest continued improvement, with an R2 value
of 0.70 (95% CI, 0.48 to 0.93; Fig 1D).
Similar results were obtained for the relationship between treat-
ment effect on DFS-2 and OS (Table 3); R2 values in the original data
set for the association between DFS-2 and OS-5, OS-6, and OS-7 were
0.73, 0.77, and 0.80, respectively; R2 values on the hypothetical data set
were 0.51, 0.67, and 0.70, respectively.
When analyzed by stage, extending survival after recurrence re-
duced the association between treatment effects on DFS-3 and OS-5 in
both stage II and stage III patients. In the original data set in stage II
patients, the R2 value for association between treatment effects on
DFS-3 and OS-5 was 0.57 (95% CI, 0.27 to 0.87), which fell to 0.38
(95% CI, 0.02 to 0.73) when survival after recurrence was doubled.
Extending OS follow-up to 6 or 7 years resulted in limited improve-
ment, with an R2 of 0.53 for OS-6 and 0.49 for OS-7 in stage II patients.
In stage III patients, extending survival after recurrence reduced the R2
values for the association between treatment effects on DFS-3 and
OS-5 from 0.84 (95% CI, 0.70 to 0.97) in the original data set to 0.55
(95% CI, 0.25 to 0.86); extending OS median follow-up to 6 or 7 years
increased the R2 values to 0.69 and 0.72, respectively.
The analysis was repeated on additional simulated data sets based
on differential extension of survival based on patient characteristics
(Table 2); results are shown in Figure 2. Consistent findings were
observed in sensitivity analyses where the association between treat-
ment effects on DFS-3 and OS-5 suffered when survival after recur-
rence was extended. The association improved between treatment
effects on DFS-3 and OS-6, with further improvement between DFS-3
and OS-7. Among the three sensitivity analyses, the most substantial
Table 1. Copula R2 Values and Corresponding 95% CIs
Factor
5-Year Median OS 6-Year Median OS 7-Year Median OS
R2 95% CI R2 95% CI R2 95% CI
Association with 3-year DFS (median)
Actual data 0.75 0.55 to 0.95 0.78 0.60 to 0.96 0.82 0.67 to 0.97
Double TRD 0.51 0.18 to 0.83 0.67 0.42 to 0.92 0.70 0.48 to 0.93
Recurrence dependent 0.54 0.23 to 0.85 0.64 0.37 to 0.91 0.76 0.56 to 0.95
Stage dependent 0.44 0.10 to 0.78 0.61 0.32 to 0.89 0.68 0.43 to 0.92
Treatment dependent (surgery only v chemotherapy) 0.29 0.0 to 0.64 0.41 0.06 to 0.76 0.49 0.16 to 0.82
Association with 2-year DFS (median)
Actual data 0.73 0.51 to 0.94 0.77 0.58 to 0.96 0.80 0.63 to 0.96
Double TRD 0.51 0.18 to 0.83 0.67 0.41 to 0.92 0.70 0.46 to 0.93
Abbreviations: OS, overall survival; DFS, disease-free survival; TRD, time from recurrence to death.
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deterioration of the association between DFS and OS was observed
when patient survival after recurrence was differentially extended
based on initial adjuvant therapy versus control.
DISCUSSION
This analysis of simulated data based on the ACCENT database sug-
gests that an extension of patient survival after recurrence will reduce
the association between the detection of a treatment effect on DFS
assessed after a relatively short duration of follow-up (in this case, a
median of 2 or 3 years) and the observed effect on OS assessed at a later
but relatively short time point (in this case, 5 years). The association
between treatment effects on DFS and OS improved if OS was evalu-
ated at a longer follow-up time. Our results imply that extended
survival after disease recurrence will require modern adjuvant colon
cancer clinical trials to observe patients for more than 5 years to verify
therapeutic benefits of adjuvant therapy on OS. These results do not
directly inform as to whether 2-year versus 3-year DFS is the optimal
end point for adjuvant trials; to obtain adequate power to use a 2-year
DFS end point, a greater number of patients may be required. The
resolution of this issue awaits future analyses on modern adjuvant
therapy trials.
The decreased association between DFS-3 and OS-5 as a result of
increasing survival after recurrence has a clear intuitive rationale.
When patients live longer after recurrence, more patients who experi-
ence recurrence within the first 3 years from chemotherapy will be
alive at the 5-year time point. In the original ACCENT data set,
median survival after recurrence was 12 months; thus, most patients
who experienced recurrence within the first 3 years had died by 5 years.
With a median survival time after recurrence of 24 months, this
proportion will decrease substantially. However, even with extended
survival after recurrence, most patients with recurrent disease will
have died by 6 or 7 years after adjuvant therapy; thus, the association
between DFS-3 and OS-6 or OS-7 intuitively should be enhanced.
Furthermore, deaths from other causes become increasingly likely as
patients become more removed from their primary colon cancer;
thus, it is unlikely that the association between DFS-3 and even OS-7
could be as strong as between DFS-3 and OS-5 when survival after
recurrence is extended, which was also demonstrated in our hypothet-
ical data sets. Our analyses on the earlier DFS end point, after 2 years of
median follow-up, were entirely consistent with the DFS-3 results.
The results were also consistent separately in stage II and III patients.
Thus, these analyses support the previous ACCENT findings that the
association between DFS and OS in trials of stage II patients only is
insufficient to declare DFS to be a valid surrogate end point in clinical
trials with only a stage II population.17
In two of the three sensitivity analyses performed, the findings
were consistent with those from the primary hypothetical data set.
However, in the sensitivity analysis where patient survival after recur-
rence was differentially extended by whether the patient received
or did not receive initial adjuvant therapy, the association between
treatment effects on DFS and OS at all time points was substantially
diminished. This is expected because, in this analysis, patients who
experience recurrence after initial surgery without adjuvant therapy
have a much longer time to death after recurrence than patients
treated initially with adjuvant therapy, thus influencing the associa-
tion between DFS and OS differentially between the two primary
study arms. Data from the MOSAIC study suggest that although there
is some differential survival after recurrence between the two treat-
ment arms in that trial (21-month median survival for patients treated
with infusional FU, LV, and oxaliplatin; 24-month median survival
for patients treated with bolus plus continuous-infusion FU/LV13),
the impact is much smaller than we used in our modeling (median
survival of 33 months after recurrence in control patients v 22 months
in treated patients). It must also be recognized that the modeling
approach used here extended the postrecurrence survival of all pa-
tients modestly and no patients to a large extreme (such as postrecur-
rent cure), when in fact, postrecurrence resections now provide a small
subset of patients ( 20%) a greatly extended survival after re-resection.
Several factors must be considered in applying these results,
based on simulated data sets, to current and future trials. First, there
are several mechanisms by which the duration from detected recur-
rence to death may be extended. Improved imaging modalities may
detect recurrent disease earlier, introducing lead-time bias and result-
ing in an apparent increase in duration from recurrence to death. This
fact by itself may alter the time points where the association between
DFS and OS may be strongest, but it will not change the overall
relationship. However, if earlier detection results in interventions that
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Fig 2. R2 values for actual data and hypothetical survival extensions based on
patient-specific characteristics.
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are potentially curative, such as secondary resection, this association
between DFS and OS will likely change as a meaningful proportion of
patients who experience recurrence become subsequent long-term
survivors. Improvements in therapy after recurrence that extend life
without cure for most patients, such as currently provided by chemo-
therapy and biologic therapy, will also impact the time points of
maximal association between treatment effects on DFS and OS but not
the fundamental relationship. In general, the paradigm of a steady,
modest extended survival after recurrences induced by the new ther-
apies is a simple, but in our opinion reasonable, reflection of results of
recent large phase III colon cancer trials. In the last decade, the median
survival in patients with advanced disease has increased from approx-
imately 12 months with FU alone to approximately 15 months with
the addition of irinotecan,3 to 19 to 20 months with the addition of
oxaliplatin to FU,2 to approximately 24 months with biologic agents
such as bevacizumab6 and cetuximab.9 The paradigm of gradual im-
provements in outcomes in patients with advanced disease also has
been established in breast and lung cancer.23 If new agents induce
dramatic changes in postrecurrence survival, the methods presented
here would be inadequate; however, such occurrences have histori-
cally been rare. With regard to whether these results are translatable to
other disease settings, we stress that end point evaluation must be
disease and treatment specific. However, the research methodology
used in the current study can be easily applied to other settings.
Critical to the implementation of this analysis to future trials is
the need to consider whether new therapeutic interventions will alter
the time course of disease recurrence. In the MOSAIC trial, the DFS
curves have remained separated out to 6 years of follow-up and have
now translated into long-term OS benefit in stage III patients.13 Adju-
vant treatments that truly prevent recurrence do not change the rela-
tionship between DFS and OS but do affect the time points of
correlation. Our results are not highly sensitive to the underlying event
times; rather, they are sensitive to the ratio of the typical time from
study entry to the full end point (in this case, OS, which is expected to
be relatively long) to the typical time to the surrogate end point (in this
case, relatively short, with median time to recurrence among patients
who experienced recurrence of 18 months). Thus, if future adjuvant
therapies truly prevent recurrence, as has been demonstrated for FU-
based therapies,24 the strong predictive relationship between DFS and
OS should also persist, albeit possibly at different time points. How-
ever, it is uncertain how targeted therapies (bevacizumab, cetuximab,
and panitumumab) may potentially change the time patterns of re-
currence when used in the adjuvant setting. If targeted therapies
change the nature of the underlying disease (ie, resulting in less aggres-
sive behavior and thus a later recurrence), then the association be-
tween treatment effects on DFS assessed at an early time point and OS
at a later time point will likely be altered, and DFS at an early time point
such as 3 years may not be a reliable end point to predict OS.
An example of how tumor biology affects this association was
shown in a previous ACCENT analysis17 that demonstrated a lower
concordance of DFS-3 and OS-5 in patients with stage II disease versus
stage III disease. This may have been, in part, a result of a lower
proportion of recurrences occurring in the first 3 years for the stage II
patients, suggesting less aggressive tumor biology. Subsequent analy-
ses showed that survival after recurrence was significantly longer in
patients with initial stage II versus stage III disease, further supporting
the theory of differences in intrinsic tumor biology between node-
negative and node-positive disease.22 If prolongation of DFS is ac-
cepted as a clinical benefit end point on its own, independent of its
association with OS, then extending DFS remains an appropriate
primary end point regardless of whether the agent truly prevents or
delays recurrence.
Continued improvements in survival after recurrence are antici-
pated with earlier detection of recurrent disease, improved treatment
regimens on recurrence, and secondary resection for cure. The poten-
tial need for prolonged follow-up further emphasizes the importance
of early end points to ensure efficient and timely evaluation of poten-
tially life-extending adjuvant therapies. DFS may be a more accurate
reflection of the true patient-relevant benefit of adjuvant treatment if
the association between DFS and OS is altered by factors subsequent to
recurrence. The extended follow-up required to observe OS improve-
ments further supports using DFS as a full clinical end point, not only
as a surrogate end point for survival.
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